AR101256A1 - Composición vacunal que comprende ipv y ciclodextrinas - Google Patents

Composición vacunal que comprende ipv y ciclodextrinas

Info

Publication number
AR101256A1
AR101256A1 ARP150102293A ARP150102293A AR101256A1 AR 101256 A1 AR101256 A1 AR 101256A1 AR P150102293 A ARP150102293 A AR P150102293A AR P150102293 A ARP150102293 A AR P150102293A AR 101256 A1 AR101256 A1 AR 101256A1
Authority
AR
Argentina
Prior art keywords
cyclodextrin
ipv
composition
antigen
vaccine
Prior art date
Application number
ARP150102293A
Other languages
English (en)
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of AR101256A1 publication Critical patent/AR101256A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composición inmunogénica que comprende al menos un serotipo del poliovirus inactivado (IPV) y al menos una ciclodextrina o derivado de la misma, especialmente b-ciclodextrina, g-ciclodextrina o 2-hidroxipropil g-ciclodextrina, y antígenos adicionales, dicha composición está protegida contra la pérdida del título IPV inducida por tiomersal. Composición inmunogénica para su uso como una vacuna así como también el uso de una ciclodextrina, o un derivado de la misma para preservar la inmunogenicidad a la IPV en presencia de tiomersal. Método para preparar una composición vacunal y método para inmunizar un huésped contra la poliomielitis. Reivindicación 3: La composición de acuerdo con cualquiera de la reivindicación 1 y 2, en donde dicha composición comprende uno o más antígenos adicionales, preferentemente seleccionados del grupo que comprende toxoide diftérico, toxoide tetánico, antígeno Pertussis, antígeno Neisseria meningitidis, antígeno de superficie de la hepatitis B y antígeno Haemophilus influenzae b (Hib).
ARP150102293A 2014-07-21 2015-07-20 Composición vacunal que comprende ipv y ciclodextrinas AR101256A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14306179 2014-07-21

Publications (1)

Publication Number Publication Date
AR101256A1 true AR101256A1 (es) 2016-12-07

Family

ID=51263343

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102293A AR101256A1 (es) 2014-07-21 2015-07-20 Composición vacunal que comprende ipv y ciclodextrinas

Country Status (2)

Country Link
AR (1) AR101256A1 (es)
WO (1) WO2016012385A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106232577B (zh) 2014-04-25 2019-02-22 味之素株式会社 免疫刺激剂
EP3368508A1 (en) 2015-10-28 2018-09-05 Ajinomoto Co., Inc. Immunostimulating agent
CN112516325B (zh) * 2019-09-18 2023-12-08 洛阳赛威生物科技有限公司 一种稳定的口蹄疫疫苗组合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
PT835663E (pt) 1992-05-23 2010-01-04 Glaxosmithkline Biolog Sa Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DK0914153T3 (da) 1996-07-02 2007-01-29 Sanofi Pasteur Ltd Multivalente DTP-poliovacciner
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
ES2645924T3 (es) * 2002-11-01 2017-12-11 Glaxosmithkline Biologicals S.A. Procedimiento de secado
NZ575272A (en) 2006-09-07 2012-02-24 Glaxosmithkline Biolog Sa Inactivated poliovirus type 1, diptheria toxoid, tetanus toxoid and killed whole-cell Bordetella pertussis vaccine
BR112013005049A2 (pt) 2010-09-02 2016-05-31 Sanofi Pasteur estabilizador para a preparação de uma composição vacina da pólio seca injetável

Also Published As

Publication number Publication date
WO2016012385A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
UY37811A (es) Una composición inmunogénica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparación de la misma
BRPI0607551A2 (pt) vacinas de combinação de helicobacter e circovìrus porcino e métodos de uso
WO2012093406A3 (en) A combination heptavalent vaccine
MX2018002728A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
PH12017500727A1 (en) Modified virus-like particles of cmv
WO2008112344A3 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
CU20190030A7 (es) Composiciones de vacunas antineumocócicas polivalentes que comprenden conjugados de polisacárido-proteína
AR092896A1 (es) Composiciones inmunogenicas
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
CO6430434A2 (es) Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas
WO2015142671A3 (en) Influenza virus vectors and uses therefor
EP2601969A3 (en) Norovirus vaccine formulations
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
AR101256A1 (es) Composición vacunal que comprende ipv y ciclodextrinas
WO2014009971A3 (en) Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
CO6430435A2 (es) Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
CU20190013A7 (es) Composiciones de vacunas multivalentes
PH12020500414A1 (en) Method for producing influenza ha split vaccine
WO2011074006A3 (en) Vaccine composition
NZ614147A (en) Equine rhinitis vaccine
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
WO2016120596A8 (en) Multi-epitopic construct
MX2021005303A (es) Composiciones inmunogenicas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure